Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome.
about
Hormonal contraceptives: pharmacology tailored to women's healthModulation of Immunity and Inflammation by the Mineralocorticoid Receptor and AldosteroneThe ubiquitous mineralocorticoid receptor: clinical implicationsHsp90 blockers inhibit adipocyte differentiation and fat mass accumulationRelationship between impaired adipogenesis of retroperitoneal adipose tissue and hypertrophic obesity: role of endogenous glucocorticoid excessCirculating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease.The glucocorticoid receptor, not the mineralocorticoid receptor, plays the dominant role in adipogenesis and adipokine production in human adipocytesSimultaneous characterization of metabolic, cardiac, vascular and renal phenotypes of lean and obese SHHF rats.Current methods of adipogenic differentiation of mesenchymal stem cellsCentral regulation of blood pressure by the mineralocorticoid receptorAndrogens and adipose tissue in males: a complex and reciprocal interplay.The multifaceted mineralocorticoid receptorVisceral adipose tissue: emerging role of gluco- and mineralocorticoid hormones in the setting of cardiometabolic alterationsPrecocious obesity predisposes the development of more severe cisplatin-induced acute kidney injury in young adult mice.Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4-Year Follow-UpPreventive and chronic mineralocorticoid receptor antagonism is highly beneficial in obese SHHF rats.Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features.Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity.Targeting the mineralocorticoid receptor in cardiovascular disease.Roles of oxidative stress, adiponectin, and nuclear hormone receptors in obesity-associated insulin resistance and cardiovascular risk.Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications.Aldosterone and the Mineralocorticoid Receptor: Risk Factors for Cardiometabolic Disorders.Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity: Insight from the EMPHASIS-HF trial.A novel combined glucocorticoid-mineralocorticoid receptor selective modulator markedly prevents weight gain and fat mass expansion in mice fed a high-fat diet.The role of mineralocorticoid receptor signaling in the cross-talk between adipose tissue and the vascular wall.Impact of Adrenal Steroids on Regulation of Adipose Tissue.Paradoxical resistance to high-fat diet-induced obesity and altered macrophage polarization in mineralocorticoid receptor-overexpressing mice.Mineralocorticoid Receptor and Aldosterone-Related Biomarkers of End-Organ Damage in Cardiometabolic Disease
P2860
Q26745814-8B616D45-668F-4CFE-A0F1-D5A2A7B7EAECQ26785911-FD3C29CF-741D-469F-B7A6-36076ED6C5E8Q26861721-511B6479-32CD-4919-94A1-4C6BA580B89EQ28542000-B580E445-FBD7-4E42-957D-9EAF8CE48677Q34311203-F7627FE3-40E5-4253-9E3B-FFCD9FB4B943Q34714245-C8F009CD-7E23-4054-AFC3-6E3842258A63Q35064186-CFE8D508-2F01-43C5-B31C-68A8BFFB5891Q35169336-1CB01A2F-00EC-44BC-A0EF-80F0AE0F8179Q35237436-A8034449-5DEF-499D-BA81-2264800AFA2DQ35293123-53CD1804-D857-45CA-B4A6-67D6429CBC53Q35659922-7EC59482-92EF-4206-8014-6F621C774702Q35906989-15099180-E6BC-4A29-8813-42880A53DBE3Q36297722-AE7E42A9-70C4-444F-9C89-2B1F1C760BD8Q36328309-AF1F73A1-EE0E-4E70-A06A-BFF9B545A592Q36437145-3A2C060D-F5C1-4694-938D-BD21E297828EQ36836343-7E31F96C-4E09-4DC0-8FFD-C93D017FFE78Q36903395-8291FD9B-13AD-49B5-A635-9F81143F9071Q37161278-7EB67F44-6C3C-4877-BFC6-1185091D9A54Q37646528-F3FACC95-72B2-4A47-974F-FDBDCEFC977CQ38074488-DB91AD22-5B46-41F2-B521-8714C3B22B43Q38267491-833AB502-F3C3-4E62-8205-7C2654D866E2Q38444730-0C02385A-5A08-4163-BC63-DAD978C5C5ACQ38525979-C15BD607-C830-4DAE-A8FE-4CAF19D3968CQ39322673-EDE6483A-6EE2-4267-8F20-97A3E71C4242Q47329092-F12B9DBC-7AC0-43A0-8862-591BB467AB9EQ47788950-EDD07151-98EF-444F-8C78-623813257819Q50068164-58416822-DB5F-47A9-A966-9331136E9918Q54614555-09960049-4F3D-4CE1-A406-34F048A5E37BQ58722306-26A5A86B-1912-48FD-85BD-13EF64EC72A6
P2860
Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Antiadipogenic effects of the ...... eatment of metabolic syndrome.
@en
Antiadipogenic effects of the ...... eatment of metabolic syndrome.
@nl
type
label
Antiadipogenic effects of the ...... eatment of metabolic syndrome.
@en
Antiadipogenic effects of the ...... eatment of metabolic syndrome.
@nl
prefLabel
Antiadipogenic effects of the ...... eatment of metabolic syndrome.
@en
Antiadipogenic effects of the ...... eatment of metabolic syndrome.
@nl
P2093
P50
P356
P1433
P1476
Antiadipogenic effects of the ...... reatment of metabolic syndrome
@en
P2093
Adeline Muscat
Andrea Fabbri
Antonella Antelmi
Caterina Mammi
Gérard Chetrite
P304
P356
10.1210/EN.2010-0674
P407
P577
2010-11-17T00:00:00Z